MedWatch

Biogen slashes price of controversial Alzheimer's drug

After a slow start for its Alzheimer's treatment, Aduhelm, US-based Biogen is attempting to kick-start sales by halving the price.

Photo: BRIAN SNYDER/REUTERS / X90051

US-based Biogen has dropped the price of its Alzheimer's treatment Aduhelm by fifty percent, Bloomberg News reports.

This has happened to light a fire under the sales, which have stagnated since the product's launch, partially because of its high price tag.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs